Die Grafik zeigt die prognostizierten Quartalsgewinne (Bereinigter Gewinn pro Aktie, EPS) und die tatsächlich erzielten Gewinne (grün: Analystenschätzungen übertroffen, rot: Analystenschätzungen verfehlt) für den ausgewählten Zeitraum.
Umsatz (USD)
Schätzung
Umsatz
Die Grafik zeigt die prognostizierten Quartalsumsätze und die tatsächlich erzielten Umsätze (grün: Analystenschätzungen übertroffen, rot: Analystenschätzungen verfehlt) für den ausgewählten Zeitraum.
Güte der Analystenschätzungen – EPS (aktueller Zeitraum)
Quartal / Datum
EPS (USD)
Schätzung (USD)
Abweichung
Quartal / Datum
Umsatz (Mio USD)
Schätzung (Mio USD)
Abweichung
Revisionen der Gewinnschätzungen
EPS-Schätzungen für die Geschäftsjahre
2026, 2027, 2028.
USANA Health Sciences (USNA) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.64 per share a year ago.
USANA Health (USNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SALT LAKE CITY, Feb. 2, 2026 /PRNewswire/ -- As organizations face rapid market disruption and evolving leadership demands, Feb. 2 marks Self-Renewal Day, a pivotal time for business leaders to recalibrate strategies and personal development. "Growth does not happen by accident; it happens by choice," said Kevin Guest, Executive Chairman & CEO at USANA Health Sciences (NYSE: USNA).
/PRNewswire/ -- The global consumer healthcare market is hitting a massive structural wall, projected to reach $362.17 billion in 2026[1]. In this high-stakes
SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE: USNA) today announced preliminary fiscal year 2025 net sales and initial net sales guidance for fiscal year 2026 ahead of its presentation at the 28th Annual ICR Conference. At the conference, Doug Hekking, CFO, and Walter Noot, COO, will discuss USANA's strategy, including the Company's initial fiscal year 2026 sales outlook. Preliminary Fiscal Year 2025 Net Sales Results The Company currently anticipates fiscal year 2025 cons.
SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE: USNA) announced today a leadership transition as part of the Company's ongoing commitment to accelerating growth and enhancing shareholder value. Kevin Guest is returning to lead the Company as Chief Executive Officer, effective immediately. Mr. Guest, who has spent more than three decades at the Company, including eight years as CEO and the last three years as Executive Chairman, has agreed to again serve as USANA's CEO and wi.
SALT LAKE CITY, Jan. 5, 2026 /PRNewswire/ -- As leaders everywhere set sights on the new year, Kevin Guest, Executive Chairman at USANA Health Sciences (NYSE: USNA), is encouraging professionals to embrace a growth mindset as the key to lasting achievement and fulfillment. "Success is about the experiences you have, the relationships you build, and the lessons you apply," said Guest, who is also the author of the bestseller, All the Right Reasons: 12 Principles for Living a Life in Harmony.
Portfolios
0
Zum Anlegen oder Bearbeiten von Portfolios müssen Sie sich anmelden oder einen Account erstellen.
Aktuelle Aktie in ein Portfolio speichern oder neues Portfolio anlegen: